Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study
Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022.
The analyst notes that though NBI-827104 lags behind its competitors, the market opportunity will be attractive given the total addressable market estimated at ~$13 billion, with no recently approved drugs in ET.
The following data readout for Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) and Praxis Precision Medicines Inc's (NASDAQ: PRAX) second Phase 2 trials are expected in 1H of 2024 and 2H of 2022, respectively.
Commenting on efficacy, given a similar mechanism of action to Jazz's JZP385 and Praxis' PRAX-944, Needham looks for a change in TETRAS-ADL of 5-6 points and TETRAS-ADL of 4-5 points.
TETRAS is designed for the rapid and valid assessment of ET severity.
On safety, JZP385 and PRAX-944 both had ~20% discontinuations.
The analyst says that if NBI-827104's safety profile can replicate its Phase 1 (~10% discontinuation).
Needham expects a single-digit upside to shares on a successful study.
Price Action: NBIX shares are up 1.77% at $97.26 during the market session on the last check Monday.
Latest Ratings for NBIX
Date | Firm | Action | From | To |
---|---|---|---|---|
Mar 2022 | Piper Sandler | Downgrades | Overweight | Neutral |
Feb 2022 | Goldman Sachs | Upgrades | Neutral | Buy |
Feb 2022 | Morgan Stanley | Maintains | Equal-Weight |
View More Analyst Ratings for NBIX
View the Latest Analyst Ratings
See more from Benzinga
What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder
Jazz Pharma's Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.